... Food and Drug Administration Breyanzi — U.S. Food and Drug Administration Kymriah — U.S. ...
... Three CAR T-cell therapy drugs have been approved to treat DLBCL, including: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesBispecific antibody treatments are another type of immunotherapy that are showing promising results, including epcoritamab-bysp (Epkinly) and glofitamab-gxbm ...
Remission and Complete Response in DLBCL: How Long It Lasts and More
... Three CAR T-cell therapy drugs have been approved to treat DLBCL, including: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesBispecific antibody treatments are another type of immunotherapy that are showing promising results, including epcoritamab-bysp (Epkinly) and glofitamab-gxbm ...
... When CAR T cells find cancer cells, they attach to them and kill them.Several CAR T-cell therapies are approved for people with relapsed DLBCL after they have tried other treatments: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) These CAR T-cell therapies show consistent responses in clinical trials ...
5 Facts To Know About Large B-Cell Lymphoma: Symptoms, Treatments, and More
... When CAR T cells find cancer cells, they attach to them and kill them.Several CAR T-cell therapies are approved for people with relapsed DLBCL after they have tried other treatments: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) These CAR T-cell therapies show consistent responses in clinical trials ...
... FDA-approved CAR T-cell therapies include: Axicabtagene ciloleucel (Yescarta) — Used for certain types of large B-cell lymphoma, follicular lymphoma, and as a second-line treatment for large B-cell lymphoma Brexucabtagene autoleucel (Tecartus) — Approved for mantle cell lymphoma Liscocabtagene maraleucel (Breyanzi) — Approved for large B-cell lymphoma ...
Immunotherapy for Lymphoma: 4 Points To Know
... FDA-approved CAR T-cell therapies include: Axicabtagene ciloleucel (Yescarta) — Used for certain types of large B-cell lymphoma, follicular lymphoma, and as a second-line treatment for large B-cell lymphoma Brexucabtagene autoleucel (Tecartus) — Approved for mantle cell lymphoma Liscocabtagene maraleucel (Breyanzi) — Approved for large B-cell lymphoma ...
... Your oncologist (cancer doctor) may recommend: Another targeted therapy, such as acalabrutinib (Calquence), pirtobrutinib (Jaypirca), venetoclax (Venclexta) — which is used off-label — or zanubrutinib (Brukinsa) Chimeric antigen receptor (CAR) T-cell therapy, such as brexucabtagene autoleucel (Tecartus) or lisocabtagene maraleucel (Breyanzi) Chemotherapies ...
Mantle Cell Lymphoma Stages: Are Most People Diagnosed at Stage 4?
... Your oncologist (cancer doctor) may recommend: Another targeted therapy, such as acalabrutinib (Calquence), pirtobrutinib (Jaypirca), venetoclax (Venclexta) — which is used off-label — or zanubrutinib (Brukinsa) Chimeric antigen receptor (CAR) T-cell therapy, such as brexucabtagene autoleucel (Tecartus) or lisocabtagene maraleucel (Breyanzi) Chemotherapies ...
... Examples of anti-CD19 therapies approved for treating DLBCL include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesIn 2023, the U.S. ...
DLBCL Relapse Rate and Treatment Options
... Examples of anti-CD19 therapies approved for treating DLBCL include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesIn 2023, the U.S. ...
... Several other drugs have recently been approved specifically for treatment of relapsed or refractory follicular lymphoma: Tisagenlecleucel (Kymriah) — Approved in May 2022 Mosunetuzumab-axgb (Lunsumio) — Approved in December 2022 Zanubrutinib (Brukinsa) — Approved in March 2024 Lisocabtagene maraleucel (Breyanzi) — Approved in May 2024 Epcoritamab-bysp ...
Follicular Lymphoma Stages and Grades: What To Expect With Progression
... Several other drugs have recently been approved specifically for treatment of relapsed or refractory follicular lymphoma: Tisagenlecleucel (Kymriah) — Approved in May 2022 Mosunetuzumab-axgb (Lunsumio) — Approved in December 2022 Zanubrutinib (Brukinsa) — Approved in March 2024 Lisocabtagene maraleucel (Breyanzi) — Approved in May 2024 Epcoritamab-bysp ...
... Some examples of CAR T-cell therapy include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Bispecific AntibodiesBispecific antibodies are a new type of drug with two parts. ...
... Some options include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) CAR T-cell therapy can lead to strong and long-lasting remissions (periods of no active disease), even after other drugs stopped working. Possible side effects may include fever, low blood pressure, or confusion. ...
6 Treatments for Large B-Cell Lymphoma
... Some options include: Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) CAR T-cell therapy can lead to strong and long-lasting remissions (periods of no active disease), even after other drugs stopped working. Possible side effects may include fever, low blood pressure, or confusion. ...
... Some examples of CAR T-cell therapy include: Tisagenlecleucel (Kymriah) Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Bispecific AntibodiesIn 2023, two bispecific antibodies were approved to treat relapsed/refractory DLBCL that hasn’t responded to other treatments. ...
Early vs. Advanced DLBCL: How Are They Treated Differently?
... Some examples of CAR T-cell therapy include: Tisagenlecleucel (Kymriah) Axicabtagene ciloleucel (Yescarta) Lisocabtagene maraleucel (Breyanzi) Bispecific AntibodiesIn 2023, two bispecific antibodies were approved to treat relapsed/refractory DLBCL that hasn’t responded to other treatments. ...
Join
